Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitors

This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... therapies. Researchers have theorised that anti-inflammatory drugs, such as IL-6

Latest news

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    JAK inhibitors such as Xeljanz and Rinvoq. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2, inhibitors, DDP4 inhibitors and injectable GLP-1 agonists.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia. ... and filgotinib’s anticipated launch this year meets

  • Pharma deals during December 2012 Pharma deals during December 2012

    company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, CYT387, in clinical development and complementary to Gilead's ... YM Bioscience / Gilead. Company acquisition. JAK kinase

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics